Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Halozyme Therapeutics
HALO
5
Workday
WDAY
US Stock MarketDetailed Quotes
CRVO CervoMed
- 9.057
- -0.093-1.02%
Trading Apr 29 11:43 ET
78.82MMarket Cap-4.48P/E (TTM)
9.337High8.950Low73.25KVolume9.130Open9.150Pre Close668.85KTurnover1.26%Turnover RatioLossP/E (Static)8.70MShares25.69052wk High2.01P/B52.51MFloat Cap1.80052wk Low--Dividend TTM5.80MShs Float3375000000.000Historical High--Div YieldTTM4.23%Amplitude1.800Historical Low9.130Avg Price1Lot Size
CervoMed Stock Forum
Sign in to post a comment
$CervoMed (CRVO.US)$ 35$ stock.
1
1
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
40
9
2
1
$CervoMed (CRVO.US)$ Let's see 13 baby
2
$CervoMed (CRVO.US)$ Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
6 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC)
Neflamapimod ...
6 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC)
Neflamapimod ...
$CervoMed (CRVO.US)$
slow and steady
slow and steady
1
2
$CervoMed (CRVO.US)$
What a run? What's the news ?
What a run? What's the news ?
No comment yet
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Sewerman : when?